|

Tafolecimab Clinical Trials

3 actively recruiting trials

▲ +1 trial since July 2026

Also known as: IBI306

Pipeline

Phase 2: 3

Top Sponsors

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
  • Second Affiliated Hospital, School of Medicine, Zhejiang University1
  • Jinghui Wang1

Indications

  • Cancer3
  • Lung Cancer2
  • Extensive Disease Small Cell Lung Cancer1
  • Extensive Stage Lung Small Cell Cancer1
  • Bladder Urothelial Carcinoma1

Other3 trials

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
Phase 2
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Phase 2
Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.